A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.
How do you think NASDAQ:ARQL will perform against the market?
Read the most recent pitches from players about ARQL.
I'm having a hard time reconciling a decent reason not to risk this stock with real money. In my opinion, at $2/share the company is poised to repeat miraculous gains in a relatively near future. Only twice in the past eleven years has this stock been this low. Its price has climbed up to as high as $10 in times past! With the company's current pipeline, a plausible economic crisis (something this sector can be relatively immune to and could therefore draw investors), and add in the fact that ArQule is presenting at the RBC Capital Markets Global Healthcare Conference coming this Tuesday... it seems likely that something positive, no matter how minute, will likely send this stock up quick. Dilution, or other bad things could happen, but I'm having a difficult time seeing it happen with this company. The fundamentals on this stock are shaky, though. This is not without risk.
Find the members with the highest scoring picks in ARQL.
The Score Leader is the player with the highest score across all their picks in ARQL.